Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -0.89%11 Quick Ratio is 6.52 as of Mar. 2026, which is 31% above its 10-year median of 4.98. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Caris Life Sciences ranks better than 67.09% on this metric.
Caris Life Sciences has a quick ratio of 6.52. It generally indicates good short-term financial strength.
The historical rank and industry rank for Caris Life Sciences's Quick Ratio or its related term are showing as below:
CAI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.83 Med: 4.98 Max: 9.36
Current: 6.52
During the past 4 years, Caris Life Sciences's highest Quick Ratio was 9.36. The lowest was 0.83. And the median was 4.98.
CAI's Quick Ratio is ranked better than 67.09% of 1410
companies
in the Biotechnology industry
Industry Median: 3.59
vs CAI: 6.52
Caris Life Sciences (NAS:CAI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Caris Life Sciences Quick Ratio Related Terms
Caris Life Sciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caris Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Caris Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a Quick Ratio of 6.52 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Caris Life Sciences and its competitors. This is 31% above median its historical median of 4.98. Over the past decade, Caris Life Sciences' Quick Ratio has ranged from 0.83 to 9.36. According to the industry distribution chart, Caris Life Sciences ranks #464 out of 1410 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Caris Life Sciences' Quick Ratio too high?
Caris Life Sciences' current Quick Ratio of 6.52 is 31% above median its 10-year median of 4.98. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 9.36. The Biotechnology industry median Quick Ratio is 3.59. Caris Life Sciences' value of 6.52 is 81.6% above this industry median. Based on the distribution chart, Caris Life Sciences ranks #464 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Quick Ratio compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #464 out of 1410 companies for Quick Ratio. This puts Caris Life Sciences in the upper half of its industry. The industry median Quick Ratio is 3.59. Caris Life Sciences' value of 6.52 is 81.6% above this benchmark. Historically, Caris Life Sciences' own Quick Ratio has ranged from 0.83 to 9.36 over the past decade. While the company's 10-year median is 4.98 vs. the industry median of 3.59, Caris Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caris Life Sciences's current Quick Ratio of 6.52 is 81.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Caris Life Sciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caris Life Sciences's current Quick Ratio is 6.52, which is 31% above median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current Quick Ratio of 6.52. The current Quick Ratio is 6.52, which is 31% above median its 10-year median of 4.98 and 81.6% above the Biotechnology industry median of 3.59. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current Quick Ratio is 6.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score
Get the complete analysis for CAI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
